# Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）

> **NCT06949111** · PHASE2 · RECRUITING · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 128 (estimated)

## Conditions studied

- Colon Cancer

## Interventions

- **RADIATION:** radiotherapy
- **DRUG:** CAPOX
- **DRUG:** Capecitabine
- **DRUG:** Iparomlimab and Tuvonralimab Injection

## Key facts

- **NCT ID:** NCT06949111
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-15
- **Primary completion:** 2027-02
- **Final completion:** 2029-03
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06949111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06949111, "Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06949111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*